Introduction
The oncogene Myc is overexpressed in B70% of human cancers and the Myc/IgH chromosomal translocation is the cause of Burkitt lymphoma (Pelengaris et al., 2002) .
Em-Myc transgenic mice overexpress Myc under control of the immunoglobulin heavy chain gene enhancer (Em), mimicking the Myc/IgH chromosomal translocation found in human Burkitt lymphomas (Adams et al., 1985) . Myc overexpression causes abnormally increased proliferation of B lymphoid cells (Langdon et al., 1986) and acquisition of additional oncogenic lesions precipitates malignant clonal pre-B or B-cell lymphomas with a median latency of B100 days (on a C57BL/6 background) (Michalak et al., 2009) .
In addition to promoting abnormally increased cell proliferation, Myc overexpression also enhances apoptotic cell death under conditions of stress, such as limited growth factor supply (Strasser et al., 1996; Pelengaris et al., 2002) . This apoptosis imposes a barrier against Myc-induced neoplastic transformation (Pelengaris et al., 2002) and, accordingly, concomitant overexpression of pro-survival Bcl-2-like proteins (Strasser et al., 1990) or loss of pro-apoptotic relatives, such as Bim (Egle et al., 2004) or Puma (Hemann et al., 2004; Garrison et al., 2008; Michalak et al., 2009) , greatly accelerates lymphomagenesis in Em-Myc mice. Proteins of the Bcl-2 family, which comprises three subgroups with distinct functions, are major regulators of apoptosis (Youle and Strasser, 2008) . The pro-survival members (Bcl-2, Bcl-x L , Bcl-w, Mcl-1 and A1) are essential for cell survival, the BH3-only proteins (for example, Bim, Puma, Bad and Noxa) initiate apoptosis signaling and Bax/Bak are required for mitochondrial outer membrane permeabilization and activation of the caspase cascade that dismantles the cells (Strasser et al., 2011) . The molecular mechanisms for Bax/Bak activation are not fully resolved but appear to involve both direct activation by BH3-only proteins as well as indirect activation by BH3-only protein-mediated blockade of the pro-survival Bcl-2 family members (Chipuk and Green, 2008; Merino et al., 2009; Strasser et al., 2011) . BH3-only proteins bind with their BH3 region to a groove on the surface of pro-survival Bcl-2 proteins, but individual members of this subgroup differ substantially in their binding specificity. Bim and Puma interact with all pro-survival proteins and this accounts (at least in part) for their potent pro-apoptotic activity (Chen et al., 2005; Kuwana et al., 2005) . Conversely, Bad and Noxa appear to be only weak killers (at least when overexpressed), and this has been attributed to their limited binding to Bcl-2, Bcl-x L and Bcl-w or Mcl-1 and A1, respectively (Chen et al., 2005; Kuwana et al., 2005) . The binding specificity of BH3-only proteins is determined by their BH3 region (Chen et al., 2005; Kuwana et al., 2005) . Therefore, the importance of Bim's ability to bind all pro-survival Bcl-2-like proteins could be investigated by generating Bim BH3 region replacement mutant knock-in mice (Merino et al., 2009) (Bouillet et al., 1999) ) animals. Thus, for optimal induction of developmentally programmed cell death (at least in the hematopoietic system), Bim must be able to interact with all pro-survival Bcl-2 family members. We have exploited these Bim BH3 region replacement mutant mice to investigate the role of Bim's binding specificity in tumor suppression, using the Em-Myc mouse lymphoma model. These studies demonstrate that for optimal suppression of Mycinduced lymphomagenesis, Bim must be able to bind all Bcl-2-like pro-survival proteins.
Results and discussion
Bim functions as a tumor suppressor in both mice (Egle et al., 2004) and humans, with loss of both Bim alleles or suppression of Bim protein expression detected in mantle cell lymphoma (Tagawa et al., 2005) and certain other B lymphoid malignancies, such as Burkitt lymphoma (Anderton et al., 2008) . The tumor suppressor activity of Bim was first demonstrated in Em-Myc mice (Egle et al., 2004) , where loss of one Bim allele shortened median survival from the normal B100 days to B77 days and loss of both alleles to 57 days. Although loss of Puma, Bmf, Bad or Noxa can also accelerate Myc-induced lymphomagenesis (Michalak et al., 2009; Frenzel et al., 2010) , loss of one allele of these genes did not have significant impact, indicating these BH3-only proteins are less potent tumor suppressors in this context than Bim. These differences between BH3-only proteins could be due to their level of expression, their specific regulation and/or their ability to bind pro-survival Bcl-2 proteins and hence their efficacy to trigger apoptosis.
The Bim
Bad and Bim Noxa mutations both accelerated lymphoma development in Em-Myc transgenic mice Although the tumor suppressive activity of Bim has been established, it is not clear whether this requires its ability to bind to all or only a limited subset of the prosurvival Bcl-2 family members. This question could be addressed by crossing Em-Myc mice with our mutant strains of mice, in which Bim has been altered to restrict its binding to Bcl-2, Bcl-x L and Bcl-w (Bim Puma mutant proteins were expressed in such tumors at levels comparable to wild-type Bim (Figure 1b) . Moreover, expression of the Bim BH3 exchange mutant proteins did not significantly affect the expression of pro-survival Mcl-1, Bcl-2 and Bcl-x L in Em-Myc lymphomas arising in these mutant animals ( Figure 1b) .
The survival of Em-Myc/Bim BH3 mutant mice was compared with the survival of control Em-Myc mice. Remarkably, a single allele mutation of Bim into either Bim Bad or Bim Noxa significantly decreased the survival of Em-Myc mice from B100 to 64 or 70 days, respectively (Figures 2a and c) . This median lifespan is similar to that previously reported for Em-Myc/Bim þ /À mice (77 days; (Egle et al., 2004) ), and consistent with the notion that Bim functions as a haplo-insufficient tumor suppressor. The Em-Myc/Bim Bad/Bad and Em-Myc/ Bim Noxa/Noxa mice became sick even more rapidly, with a median survival of 50 and 58 days, respectively (Figure 2c ). This reduction in median survival Noxa/Noxa and Em-Myc/Bim Puma/Puma mice (extracts from two different mice for each genotype). Western blotting was carried out by standard procedures, using protein extracts generated by lysis of lymphoma cell suspensions in a buffer (containing 20 mM Tris-pH 7.4, 135 mM NaCl, 1.5 mM MgCl 2 , 1mM EGTA, 10% glycerol, 1% Triton-X 100, protease inhibitors MiniComplete and EDTA free, Roche, Dee Why, NSW, Australia). Proteins were detected using antibodies to Bim (14A8 or 3C5, ENZO, New York, NY, USA), Bcl-2 (BD Pharmingen, San Diego, CA, USA), Bcl-x L (BD Bioscience, San Diego, CA, USA), Mcl-1 (Rockland, Gilbertsville, PA, USA) or Actin (Sigma, St Louis, MO, USA). Secondary antibodies were horseradish peroxidase-conjugated, and detected using enhanced chemiluminescence (Healthcare).
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is remarkably similar to the 57 days reported for Em-Myc/Bim À/À mice (Egle et al., 2004) . Importantly, all the mice used in the present study were of the same genetic background (C57BL/6) as the mice used in our former study (Egle et al., 2004) . Thus, in this model of tumorigenesis, Bim Bad and Bim Noxa proteins behaved as complete loss-of-function mutants of Bim, indicating that in B lymphoid cells undergoing Em-Myc-induced neoplastic transformation, the life-versus-death decision must be very tightly balanced. As lymphomagenesis is accelerated both by disabling Bim from binding to either Bcl-2, Bcl-x L and Bcl-w (Bim Noxa ) or by preventing its interaction with Mcl-1 plus A1 (Bim Bad ), we hypothesize that both of these subgroups of pro-survival Bcl-2 proteins must be critical to sustain pre-leukemic Em-Myc B lymphoid cells undergoing neoplastic transformation. Consistent with a role for Mcl-1 in such a process, its haplo-insufficiency protects mice from Myc-induced acute myeloid leukemia development (Xiang et al., 2010) . As for the relative importance of endogenous expression of Bcl-2, Bcl-x L or Bcl-w in Em-Myc-induced lymphomagenesis, we predict that Bcl-x L is most critical, given that loss of Bcl-2 had no impact on this disease (Kelly et al., 2007) , and that Bcl-x L but not Bcl-w is expressed at readily detectable levels in pre-malignant Em-Myc B lymphoid cells (Michalak et al., 2009 ).
The Bim
Puma mutation had no significant impact on lymphoma development in Em-Myc mice We have previously shown that the replacement of the BH3 domain of Bim with the BH3 domain of Puma did not impair its ability to bind to all pro-survival Bcl-2-like proteins (Merino et al., 2009) . This mutation did, however, cause a significant, albeit relatively minor, increase in leukocytes, indicating that actions of Bim that are independent of its ability to bind to pro-survival Bcl-2 family, such as direct interaction with Bax/Bak, must also be critical for optimal activity in developmentally programmed cell death (at least in the hematopoietic system). Interestingly, the median lifespans of EmMyc/Bim Puma/ þ (110 days) and (despite a trend toward accelerated disease) even of the Em-Myc/Bim Puma/Puma mice (84 days) was not significantly different from the median survival of control Em-Myc mice (Figures 2b and c) . This indicates that the actions of Bim that are independent of its ability to bind pro-survival Bcl-2-like proteins are not essential for its tumor suppressive function, at least in Em-Myc mice. This apparent discrepancy with our previous conclusions (Merino et al., 2009 ) might simply be due to a difference of experimental setting. None of the cells considered in our former study were malignant, whereas they are in this study. This does, however, not exclude that direct activation of Bax/Bak can have a role in killing of Em-Myc B lymphoid cells undergoing transformation (Letai et al., 2004) , as this function might be accomplished by another BH3-only protein present in these cells (for example, Puma or Noxa) as long as Bim (that is, Bim Puma in this case) can neutralize all pro-survival Bcl-2 proteins.
Bad and Bim Noxa but not the Bim Puma mutation enhanced the severity of Em-Myc lymphoma At autopsy, the spleen weights of all Em-Myc/Bim BH3 exchange mutant mice were similar to those of sick control Em-Myc littermates (Figure 3a) . Remarkably, however, the Em-Myc/Bim
Bad/Bad and Em-Myc/Bim Noxa/Noxa mice had significantly higher white blood cell counts (Figure 3b) . Conversely, the Em-Myc/Bim Puma/Puma mice showed similar leukemic burden compared with control Em-Myc mice (Figure 3b) . Finally, immunophenotyping did not reveal significant differences between lymphomas from the various genotypes of mice. B220
þ IgM þ B lymphomas were slightly more abundant in the control Em-Myc mice, whereas B220 þ sIgM À pre-B lymphomas predominated in all other genotypes (Figure 3c ).
In conclusion, this study demonstrates that the binding to pro-survival Bcl-2 family members has an important role in the tumor suppressor activity of the BH3-only protein Bim. The data also indicate that Mcl-1 and Bcl-x L may have critical roles in sustaining the survival of pre-leukemic Em-Myc B lymphoid cells while they are acquiring additional oncogenic lesions that promote their progression to full malignancy. This hypothesis could be tested by generating Em-Myc mice, in which Mcl-1 or Bcl-x L can be deleted specifically in B lymphoid cells. If proven correct, one may consider to target Bcl-x L and/or Mcl-1 as a strategy for early intervention to prevent or delay Myc-induced tumorigenesis if early detection of pre-malignant lesions is possible or if patients are known to be predestined to develop such tumors.
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